UCB's Global Corporate Website

Driving medicine forward by sharing scientific knowledge

Posted by
Andrea Levin, Global Communications & Company Reputation
This is one of the busiest times of the year for medical conferences and an important opportunity for UCB to share the scientific data we generate through our research. The benefits run both ways, of course, and our scientists are always closely studying the latest scientific knowledge published at major events in our areas of expertise.

Ultimately, the biggest beneficiaries are patients. If we reflect on how far our understanding of diseases has come in recent decades, it is clear that medical research has seen major progress. From one month to the next, the changes may seem incremental but take a step back and you will see how dramatic the revolution has been.

Today, research has advanced our understanding of severe diseases like rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthrits (axSpA),  autoimmune disorders where the body mistakenly attacks its own immune system. These diseases cause significant inflammation of the joints and spine and can be very disabling.

Scientific research over the last few decades has revealed how these diseases manifest, often by overproduction of certain genes. This understanding has allowed UCB to create drugs that specifically target these genes, as well as conduct research to better understand the most appropriate patients for specific therapies.

That is why UCB is so active at medical congresses. We have seen the value that sharing and exchanging scientific research can bring to patients.

However, we also know that we are a long way from fully understanding how to optimise treatment for all patients with immunological diseases; more work needs to be done.

At the American College of Rheumatology Annual Meeting in San Francisco this week (6-11 November), we are presenting the latest data from our immunology portfolio. A total of 19 studies will be shared, many of them exploring how our core medicine in this field can be used to improve the lives of a broad range of patients.

We are also publishing data from new studies on investigational treatments for systemic lupus erythematosus and Söjrgen’s Syndrome.

Active attendance at influential scientific conferences like this is an important part of our contribution to improving patients’ lives. Last month we contributed several presentations to the American College of Gastroenterology (ACG) 2015 Annual Scientific Meeting, taking place in Honolulu (16-21 October).

The focus here was mainly on Crohn's disease, a type of inflammatory bowel disease (IBD), which is chronic, progressive, and often destructive.

UCB will continue to invest in research and to add real value to medical science by participating in scientific congresses. We are there to learn and share so that we can improve patient care.

Leave a Comment

By submitting your personal data, you agree with UCB's Data Privacy Policy. Furthermore, for more information on the terms of use of this website please visit our Legal Notice, accessible here.

5 + 0 =

Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.